Collectively, data from clinical trials indicated that neoadjuvant EGFR-TKIs, including erlotinib, afatinib, and osimertinib, could improve the pathological response rate and PFS of NSCLC patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.